首页 > 最新文献

Antibiotics最新文献

英文 中文
Returned Rate and Changed Patterns of Systemic Antibiotic Use in Ambulatory Care in Hungary after the Pandemic—A Longitudinal Ecological Study 大流行后匈牙利非住院治疗中全身使用抗生素的返修率和变化模式--纵向生态学研究
Pub Date : 2024-09-05 DOI: 10.3390/antibiotics13090848
Helga Hambalek, Mária Matuz, Roxána Ruzsa, Erika Papfalvi, Róbert Nacsa, Zsófia Engi, Márta Csatordai, Gyöngyvér Soós, Edit Hajdú, Dezső Csupor, Ria Benkő
The COVID-19 pandemic affected the epidemiology of infectious diseases and changed the operation of health care systems and health care seeking behavior. Our study aimed to analyze the utilization of systemic antibiotics in ambulatory care in Hungary after the COVID-19 pandemic and compare it to the period before COVID. We defined three periods (24 months each): Before COVID, COVID, and After COVID. Monthly trends in systemic antibiotic (J01) use were calculated using the WHO ATC-DDD index and expressed as DDD/1000 inhabitants/day (DID) and number of exposed patients per active agent. The data were further categorized by the WHO AWaRe classification. In the After COVID period, we detected almost the same (11.61 vs. 11.11 DID) mean monthly use of systemic antibiotics in ambulatory care compared to the Before COVID period. We observed a decrease in the seasonality index in the After COVID period (46.86% vs. 39.86%). In the After COVID period, the use of cephalosporins and quinolones decreased significantly, while in the case of macrolides, a significant increase was observed compared to the Before COVID period, with excessive azithromycin use (66,869 vs. 97,367 exposed patients). This study demonstrated significant changes in the pattern of ambulatory care antibiotic use in Hungary.
COVID-19 大流行影响了传染病的流行病学,改变了医疗保健系统的运作和就医行为。我们的研究旨在分析 COVID-19 大流行后匈牙利门诊护理中全身性抗生素的使用情况,并与 COVID 之前的情况进行比较。我们定义了三个时期(每个时期 24 个月):COVID之前、COVID期间和COVID之后。使用世界卫生组织的 ATC-DDD 指数计算全身抗生素 (J01) 使用的月度趋势,并以 DDD/1000 居民/天 (DID) 和每种活性制剂的暴露患者人数表示。数据按世界卫生组织 AWaRe 分类法进一步分类。与 COVID 之前相比,在 COVID 之后,我们发现门诊护理中系统性抗生素的月平均使用量几乎相同(11.61 对 11.11 DID)。在 COVID 之后,我们发现季节性指数有所下降(46.86% 对 39.86%)。在 COVID 之后,头孢菌素类和喹诺酮类药物的使用显著减少,而与 COVID 之前相比,大环内酯类药物的使用显著增加,其中阿奇霉素的使用过多(66,869 对 97,367)。这项研究表明,匈牙利非住院治疗抗生素使用模式发生了重大变化。
{"title":"Returned Rate and Changed Patterns of Systemic Antibiotic Use in Ambulatory Care in Hungary after the Pandemic—A Longitudinal Ecological Study","authors":"Helga Hambalek, Mária Matuz, Roxána Ruzsa, Erika Papfalvi, Róbert Nacsa, Zsófia Engi, Márta Csatordai, Gyöngyvér Soós, Edit Hajdú, Dezső Csupor, Ria Benkő","doi":"10.3390/antibiotics13090848","DOIUrl":"https://doi.org/10.3390/antibiotics13090848","url":null,"abstract":"The COVID-19 pandemic affected the epidemiology of infectious diseases and changed the operation of health care systems and health care seeking behavior. Our study aimed to analyze the utilization of systemic antibiotics in ambulatory care in Hungary after the COVID-19 pandemic and compare it to the period before COVID. We defined three periods (24 months each): Before COVID, COVID, and After COVID. Monthly trends in systemic antibiotic (J01) use were calculated using the WHO ATC-DDD index and expressed as DDD/1000 inhabitants/day (DID) and number of exposed patients per active agent. The data were further categorized by the WHO AWaRe classification. In the After COVID period, we detected almost the same (11.61 vs. 11.11 DID) mean monthly use of systemic antibiotics in ambulatory care compared to the Before COVID period. We observed a decrease in the seasonality index in the After COVID period (46.86% vs. 39.86%). In the After COVID period, the use of cephalosporins and quinolones decreased significantly, while in the case of macrolides, a significant increase was observed compared to the Before COVID period, with excessive azithromycin use (66,869 vs. 97,367 exposed patients). This study demonstrated significant changes in the pattern of ambulatory care antibiotic use in Hungary.","PeriodicalId":8151,"journal":{"name":"Antibiotics","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic Characterization of Extended-Spectrum β-Lactamase-Producing and Third-Generation Cephalosporin-Resistant Escherichia coli Isolated from Stools of Primary Healthcare Patients in Ethiopia 从埃塞俄比亚初级保健患者粪便中分离出的产广谱β-乳酰胺酶和耐第三代头孢菌素大肠埃希菌的基因组特征描述
Pub Date : 2024-09-05 DOI: 10.3390/antibiotics13090851
Deneke Wolde, Tadesse Eguale, Girmay Medhin, Aklilu Feleke Haile, Haile Alemayehu, Adane Mihret, Mateja Pirs, Katja Strašek Smrdel, Jana Avberšek, Darja Kušar, Tjaša Cerar Kišek, Tea Janko, Andrej Steyer, Marjanca Starčič Erjavec
The global spread of antimicrobial resistance genes (ARGs) in Escherichia coli is a major public health concern. The aim of this study was to investigate the genomic characteristics of extended-spectrum β-lactamase (ESBL)-producing and third-generation cephalosporin-resistant E. coli from a previously obtained collection of 260 E. coli isolates from fecal samples of patients attending primary healthcare facilities in Addis Ababa and Hossana, Ethiopia. A total of 29 E. coli isolates (19 phenotypically confirmed ESBL-producing and 10 third-generation cephalosporin-resistant isolates) were used. Whole-genome sequencing (NextSeq 2000 system, Illumina) and bioinformatic analysis (using online available tools) were performed to identify ARGs, virulence-associated genes (VAGs), mobile genetic elements (MGEs), serotypes, sequence types (STs), phylogeny and conjugative elements harbored by these isolates. A total of 7 phylogenetic groups, 22 STs, including ST131, and 23 serotypes with different VAGs were identified. A total of 31 different acquired ARGs and 10 chromosomal mutations in quinolone resistance-determining regions (QRDRs) were detected. The isolates harbored diverse types of MGEs, with IncF plasmids being the most prevalent (66.7%). Genetic determinants associated with conjugative transfer were identified in 75.9% of the E. coli isolates studied. In conclusion, the isolates exhibited considerable genetic diversity and showed a high potential for transferability of ARGs and VAGs. Bioinformatic analyses also revealed that the isolates exhibited substantial genetic diversity in phylogenetic groups, sequence types (ST) and serogroups and were harboring a variety of virulence-associated genes (VAGs). Thus, the studied isolates have a high potential for transferability of ARGs and VAGs.
大肠埃希菌的抗菌药耐药基因(ARGs)在全球的传播是一个重大的公共卫生问题。本研究的目的是从埃塞俄比亚亚的斯亚贝巴和霍萨纳初级医疗机构就诊患者的粪便样本中收集的 260 个大肠杆菌分离物中,研究产生广谱β-内酰胺酶(ESBL)和第三代头孢菌素耐药大肠杆菌的基因组特征。共使用了 29 个大肠杆菌分离株(19 个经表型确认可产生 ESBL 的分离株和 10 个耐第三代头孢菌素的分离株)。通过全基因组测序(NextSeq 2000 系统,Illumina)和生物信息学分析(使用在线工具),确定了这些分离株所携带的 ARGs、毒力相关基因(VAGs)、移动遗传元件(MGEs)、血清型、序列类型(STs)、系统发育和共轭元件。共鉴定出 7 个系统发育群、22 种 ST(包括 ST131)和 23 种具有不同 VAG 的血清型。共检测到 31 个不同的获得性 ARGs 和 10 个喹诺酮耐药性决定区(QRDRs)的染色体突变。分离株携带不同类型的 MGEs,其中以 IncF 质粒最为普遍(66.7%)。在所研究的 75.9% 的大肠杆菌分离物中发现了与共轭传递相关的基因决定簇。总之,分离物表现出相当大的遗传多样性,并显示出 ARGs 和 VAGs 的高转移潜力。生物信息学分析还显示,分离物在系统发生群、序列类型(ST)和血清群中表现出相当大的遗传多样性,并携带多种毒力相关基因(VAGs)。因此,所研究的分离株具有很高的 ARGs 和 VAGs 转移潜力。
{"title":"Genomic Characterization of Extended-Spectrum β-Lactamase-Producing and Third-Generation Cephalosporin-Resistant Escherichia coli Isolated from Stools of Primary Healthcare Patients in Ethiopia","authors":"Deneke Wolde, Tadesse Eguale, Girmay Medhin, Aklilu Feleke Haile, Haile Alemayehu, Adane Mihret, Mateja Pirs, Katja Strašek Smrdel, Jana Avberšek, Darja Kušar, Tjaša Cerar Kišek, Tea Janko, Andrej Steyer, Marjanca Starčič Erjavec","doi":"10.3390/antibiotics13090851","DOIUrl":"https://doi.org/10.3390/antibiotics13090851","url":null,"abstract":"The global spread of antimicrobial resistance genes (ARGs) in Escherichia coli is a major public health concern. The aim of this study was to investigate the genomic characteristics of extended-spectrum β-lactamase (ESBL)-producing and third-generation cephalosporin-resistant E. coli from a previously obtained collection of 260 E. coli isolates from fecal samples of patients attending primary healthcare facilities in Addis Ababa and Hossana, Ethiopia. A total of 29 E. coli isolates (19 phenotypically confirmed ESBL-producing and 10 third-generation cephalosporin-resistant isolates) were used. Whole-genome sequencing (NextSeq 2000 system, Illumina) and bioinformatic analysis (using online available tools) were performed to identify ARGs, virulence-associated genes (VAGs), mobile genetic elements (MGEs), serotypes, sequence types (STs), phylogeny and conjugative elements harbored by these isolates. A total of 7 phylogenetic groups, 22 STs, including ST131, and 23 serotypes with different VAGs were identified. A total of 31 different acquired ARGs and 10 chromosomal mutations in quinolone resistance-determining regions (QRDRs) were detected. The isolates harbored diverse types of MGEs, with IncF plasmids being the most prevalent (66.7%). Genetic determinants associated with conjugative transfer were identified in 75.9% of the E. coli isolates studied. In conclusion, the isolates exhibited considerable genetic diversity and showed a high potential for transferability of ARGs and VAGs. Bioinformatic analyses also revealed that the isolates exhibited substantial genetic diversity in phylogenetic groups, sequence types (ST) and serogroups and were harboring a variety of virulence-associated genes (VAGs). Thus, the studied isolates have a high potential for transferability of ARGs and VAGs.","PeriodicalId":8151,"journal":{"name":"Antibiotics","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progress and Challenges: Implementation of the UK Antimicrobial Resistance National Action Plan 2019–2024 within the Beef Cattle Sub-Sector 进展与挑战:在肉牛分行业内实施《2019-2024 年英国抗菌药耐药性国家行动计划
Pub Date : 2024-09-04 DOI: 10.3390/antibiotics13090839
Houda Bennani, Louise Whatford, Jessica Myers, Nicholas Mays, Rebecca Glover, Barbara Häsler
The five-year UK antimicrobial resistance (AMR) National Action Plan (NAP) was published in 2019 focusing on reducing the need for, and unintentional exposure to antimicrobials (AMs); optimising the use of AMs; and investing in innovation, supply and access of AMs. This study aimed to evaluate the progress made in the beef cattle sub-sector in addressing specific NAP commitments related to improving animal health and welfare and responsible antimicrobial use (AMU). A thematic analysis was conducted of 21 semi-structured interviews with stakeholders from government organisations, farms, veterinary practices, levy boards and livestock associations. The findings indicate substantial progress, with various initiatives implemented targeting data collection, farmer and veterinarian engagement, and herd health planning. However, there remain a number of challenges and barriers that need to be addressed in order to assess the impacts of these initiatives, such as the availability of AMU and AMR data. Ensuring the adequacy of resources was found to be critical for the sustainability of effective initiatives, considering competing demands on people’s time. Additionally, the importance of other outcomes from these initiatives such as developing and strengthening the farmer–veterinarian relationship should not be underestimated since it is fundamental to successfully addressing issues such as AMR.
为期五年的英国抗菌药耐药性(AMR)国家行动计划(NAP)于 2019 年发布,重点关注减少对抗菌药(AMs)的需求和无意接触;优化 AMs 的使用;以及投资于 AMs 的创新、供应和获取。本研究旨在评估肉牛分行业在履行与改善动物健康和福利以及负责任地使用抗菌药 (AMU) 相关的具体国家行动方案承诺方面所取得的进展。我们对 21 个半结构式访谈进行了专题分析,访谈对象包括政府组织、农场、兽医诊所、征收委员会和畜牧协会的利益相关者。研究结果表明,随着针对数据收集、农场主和兽医参与以及畜群健康规划的各种举措的实施,取得了实质性进展。然而,为了评估这些举措的影响,仍有一些挑战和障碍需要解决,例如 AMU 和 AMR 数据的可用性。考虑到对人们时间的竞争性需求,确保充足的资源对于有效举措的可持续性至关重要。此外,不应低估这些举措所产生的其他成果的重要性,如发展和加强农民与兽医之间的关系,因为这对于成功解决 AMR 等问题至关重要。
{"title":"Progress and Challenges: Implementation of the UK Antimicrobial Resistance National Action Plan 2019–2024 within the Beef Cattle Sub-Sector","authors":"Houda Bennani, Louise Whatford, Jessica Myers, Nicholas Mays, Rebecca Glover, Barbara Häsler","doi":"10.3390/antibiotics13090839","DOIUrl":"https://doi.org/10.3390/antibiotics13090839","url":null,"abstract":"The five-year UK antimicrobial resistance (AMR) National Action Plan (NAP) was published in 2019 focusing on reducing the need for, and unintentional exposure to antimicrobials (AMs); optimising the use of AMs; and investing in innovation, supply and access of AMs. This study aimed to evaluate the progress made in the beef cattle sub-sector in addressing specific NAP commitments related to improving animal health and welfare and responsible antimicrobial use (AMU). A thematic analysis was conducted of 21 semi-structured interviews with stakeholders from government organisations, farms, veterinary practices, levy boards and livestock associations. The findings indicate substantial progress, with various initiatives implemented targeting data collection, farmer and veterinarian engagement, and herd health planning. However, there remain a number of challenges and barriers that need to be addressed in order to assess the impacts of these initiatives, such as the availability of AMU and AMR data. Ensuring the adequacy of resources was found to be critical for the sustainability of effective initiatives, considering competing demands on people’s time. Additionally, the importance of other outcomes from these initiatives such as developing and strengthening the farmer–veterinarian relationship should not be underestimated since it is fundamental to successfully addressing issues such as AMR.","PeriodicalId":8151,"journal":{"name":"Antibiotics","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence and Predictors of Healthcare-Associated Infections in Patients Admitted to a Temporary Intensive Care Unit during the COVID-19 Pandemic Waves: A Two-Year (2021–2023) Retrospective Cohort Study in Rome, Italy COVID-19 大流行期间入住临时重症监护病房的患者中医疗保健相关感染的发生率和预测因素:意大利罗马一项为期两年(2021-2023 年)的回顾性队列研究
Pub Date : 2024-09-04 DOI: 10.3390/antibiotics13090842
Antonio Sciurti, Valentina Baccolini, Mariateresa Ceparano, Claudia Isonne, Giuseppe Migliara, Jessica Iera, Francesco Alessandri, Giancarlo Ceccarelli, Carolina Marzuillo, Guglielmo Tellan, Maria De Giusti, Francesco Pugliese, Paolo Villari, the Collaborating Group
To manage the number of critical COVID-19 patients, Umberto I Teaching Hospital in Rome established a temporary ICU on March 1, 2021. This study investigated the incidence and risk factors of healthcare-associated infections (HAIs) among these patients during various COVID-19 waves. Patients were grouped by admission date according to the dominant SARS-CoV-2 variant prevalent at the time (Alpha, Delta, Omicron BA.1, Omicron BA.2, Omicron BA.5, and Omicron XBB). First-HAI and mortality rates were calculated per 1000 patient-days. Predictors of first-HAI occurrence were investigated using a multivariable Fine–Gray regression model considering death as a competing event. Among 355 admitted patients, 27.3% experienced at least one HAI, and 49.6% died. Patient characteristics varied over time, with older and more complex cases in the later phases, while HAI and mortality rates were higher in the first year. Pathogens responsible for HAIs varied over time, with first Acinetobacter baumannii and then Klebsiella pneumoniae being progressively predominant. Multivariable analysis confirmed that, compared to Alpha, admission during the Omicron BA.1, BA.2, BA.5, and XBB periods was associated with lower hazards of HAI. Despite worsening COVID-19 patient conditions, late-phase HAI rates decreased, likely due to evolving pathogen characteristics, improved immunity, but also better clinical management, and adherence to infection prevention practices. Enhanced HAI prevention in emergency situations is crucial.
为了管理 COVID-19 危重病人的数量,罗马翁贝托一世教学医院于 2021 年 3 月 1 日成立了临时重症监护室。本研究调查了这些患者在 COVID-19 各次波及期间的医护相关感染 (HAI) 发生率和风险因素。根据当时流行的 SARS-CoV-2 主要变异体(Alpha、Delta、Omicron BA.1、Omicron BA.2、Omicron BA.5 和 Omicron XBB),按入院日期对患者进行分组。首次 HAI 发生率和死亡率按每 1000 个患者日计算。使用多变量 Fine-Gray 回归模型对首次发生急性呼吸道感染的预测因素进行了研究,并将死亡作为一个竞争事件。在355名入院患者中,27.3%至少发生过一次HAI,49.6%死亡。患者特征随时间而变化,后期病例年龄更大、更复杂,而第一年的 HAI 和死亡率更高。造成 HAI 的病原体也随时间变化,首先是鲍曼不动杆菌,然后是肺炎克雷伯菌,并逐渐成为主要病原体。多变量分析证实,与 Alpha 相比,在 Omicron BA.1、BA.2、BA.5 和 XBB 期间入院的患者发生 HAI 的风险较低。尽管 COVID-19 患者的病情恶化,但后期阶段的 HAI 发生率却有所下降,这可能是由于病原体特征不断变化、免疫力提高、临床管理改善以及坚持感染预防实践所致。在紧急情况下加强 HAI 预防至关重要。
{"title":"Incidence and Predictors of Healthcare-Associated Infections in Patients Admitted to a Temporary Intensive Care Unit during the COVID-19 Pandemic Waves: A Two-Year (2021–2023) Retrospective Cohort Study in Rome, Italy","authors":"Antonio Sciurti, Valentina Baccolini, Mariateresa Ceparano, Claudia Isonne, Giuseppe Migliara, Jessica Iera, Francesco Alessandri, Giancarlo Ceccarelli, Carolina Marzuillo, Guglielmo Tellan, Maria De Giusti, Francesco Pugliese, Paolo Villari, the Collaborating Group","doi":"10.3390/antibiotics13090842","DOIUrl":"https://doi.org/10.3390/antibiotics13090842","url":null,"abstract":"To manage the number of critical COVID-19 patients, Umberto I Teaching Hospital in Rome established a temporary ICU on March 1, 2021. This study investigated the incidence and risk factors of healthcare-associated infections (HAIs) among these patients during various COVID-19 waves. Patients were grouped by admission date according to the dominant SARS-CoV-2 variant prevalent at the time (Alpha, Delta, Omicron BA.1, Omicron BA.2, Omicron BA.5, and Omicron XBB). First-HAI and mortality rates were calculated per 1000 patient-days. Predictors of first-HAI occurrence were investigated using a multivariable Fine–Gray regression model considering death as a competing event. Among 355 admitted patients, 27.3% experienced at least one HAI, and 49.6% died. Patient characteristics varied over time, with older and more complex cases in the later phases, while HAI and mortality rates were higher in the first year. Pathogens responsible for HAIs varied over time, with first Acinetobacter baumannii and then Klebsiella pneumoniae being progressively predominant. Multivariable analysis confirmed that, compared to Alpha, admission during the Omicron BA.1, BA.2, BA.5, and XBB periods was associated with lower hazards of HAI. Despite worsening COVID-19 patient conditions, late-phase HAI rates decreased, likely due to evolving pathogen characteristics, improved immunity, but also better clinical management, and adherence to infection prevention practices. Enhanced HAI prevention in emergency situations is crucial.","PeriodicalId":8151,"journal":{"name":"Antibiotics","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is Taurolidine Irrigation Effective in Preventing Surgical Site Infection during Fracture Surgery? Taurolidine 冲洗对预防骨折手术中的手术部位感染有效吗?
Pub Date : 2024-09-04 DOI: 10.3390/antibiotics13090841
Shubham Yashwant Dakhode, Woo Sub Kim, Hyun Jin Kim, Seung Yeol Lee
Taurolidine, known for its broad-spectrum antimicrobial properties and low toxicity, has shown promise in reducing infections in various surgical settings. However, it has not been extensively evaluated in orthopedic surgery. This study assessed the efficacy of taurolidine irrigation in reducing surgical site infections in patients undergoing ankle fracture surgery. A retrospective review was conducted for patients >20 years old who underwent ankle fracture surgery between March 2016 and March 2023, with follow-ups exceeding 6 months. Patients were classified into the following two groups: those who underwent normal saline (NS) irrigation and those who underwent taurolidine irrigation. Minor infections were defined as requiring additional oral antibiotics postoperatively, while major infections were characterized by hospitalization or reoperation due to infection within 3 months. Of 844 patients, 688 were included. The taurolidine group (n = 328) had a significant reduction in minor infections (7.3% vs. 22.5%, odds ratio = 0.410, p = 0.028) compared to the NS group (n = 360). Major infections were fewer in the NS group (1.2% vs. 0%, p = 0.051), but the number of cases was too small for reliable analysis. Taurolidine irrigation significantly reduces the occurrence of minor infections in ankle fracture surgeries when compared to normal saline irrigation.
滔罗尼定以其广谱抗菌特性和低毒性而闻名,在减少各种手术环境中的感染方面显示出良好的前景。然而,在骨科手术中尚未对其进行广泛评估。本研究评估了滔罗匹定冲洗对减少踝关节骨折手术患者手术部位感染的疗效。研究人员对 2016 年 3 月至 2023 年 3 月期间接受踝关节骨折手术的 20 岁以上患者进行了回顾性研究,随访时间超过 6 个月。患者被分为以下两组:接受生理盐水(NS)冲洗的患者和接受妥洛尼定(taurolidine)冲洗的患者。轻度感染的定义是术后需要额外口服抗生素,而重度感染的特征是 3 个月内因感染住院或再次手术。在 844 名患者中,有 688 人被纳入研究。与 NS 组(n = 360)相比,他乐定组(n = 328)的轻度感染显著减少(7.3% vs. 22.5%,几率比 = 0.410,p = 0.028)。NS 组的严重感染率较低(1.2% 对 0%,p = 0.051),但病例数太少,无法进行可靠的分析。与普通生理盐水冲洗相比,妥洛尼定冲洗可明显减少踝关节骨折手术中轻微感染的发生。
{"title":"Is Taurolidine Irrigation Effective in Preventing Surgical Site Infection during Fracture Surgery?","authors":"Shubham Yashwant Dakhode, Woo Sub Kim, Hyun Jin Kim, Seung Yeol Lee","doi":"10.3390/antibiotics13090841","DOIUrl":"https://doi.org/10.3390/antibiotics13090841","url":null,"abstract":"Taurolidine, known for its broad-spectrum antimicrobial properties and low toxicity, has shown promise in reducing infections in various surgical settings. However, it has not been extensively evaluated in orthopedic surgery. This study assessed the efficacy of taurolidine irrigation in reducing surgical site infections in patients undergoing ankle fracture surgery. A retrospective review was conducted for patients >20 years old who underwent ankle fracture surgery between March 2016 and March 2023, with follow-ups exceeding 6 months. Patients were classified into the following two groups: those who underwent normal saline (NS) irrigation and those who underwent taurolidine irrigation. Minor infections were defined as requiring additional oral antibiotics postoperatively, while major infections were characterized by hospitalization or reoperation due to infection within 3 months. Of 844 patients, 688 were included. The taurolidine group (n = 328) had a significant reduction in minor infections (7.3% vs. 22.5%, odds ratio = 0.410, p = 0.028) compared to the NS group (n = 360). Major infections were fewer in the NS group (1.2% vs. 0%, p = 0.051), but the number of cases was too small for reliable analysis. Taurolidine irrigation significantly reduces the occurrence of minor infections in ankle fracture surgeries when compared to normal saline irrigation.","PeriodicalId":8151,"journal":{"name":"Antibiotics","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing of Candida auris: Underestimation of Fluconazole Resistance by MICRONAUT-AM and Overestimation of Amphotericin B Resistance by Etest 评估 Etest 和 MICRONAUT-AM 检测法对白色念珠菌的抗真菌药敏试验:MICRONAUT-AM 低估了氟康唑的耐药性,Etest 高估了两性霉素 B 的耐药性
Pub Date : 2024-09-04 DOI: 10.3390/antibiotics13090840
Mohammad Asadzadeh, Suhail Ahmad, Wadha Alfouzan, Inaam Al-Obaid, Bram Spruijtenburg, Eelco F. J. Meijer, Jacques F. Meis, Eiman Mokaddas
Multidrug-resistant Candida auris has recently caused major outbreaks in healthcare facilities. Rapid and accurate antifungal susceptibility testing (AST) of C. auris is crucial for proper management of invasive infections. The Commercial Sensititre Yeast One and Vitek 2 methods underestimate or overestimate the resistance of C. auris to fluconazole and amphotericin B (AMB). This study evaluated the AST results of C. auris against fluconazole and AMB by gradient-MIC-strip (Etest) and broth microdilution-based MICRONAUT-AM-EUCAST (MCN-AM) assays. Clinical C. auris isolates (n = 121) identified by phenotypic and molecular methods were tested. Essential agreement (EA, ±1 two-fold dilution) between the two methods and categorical agreement (CA) based on the Centers for Disease Control and Prevention’s (CDC’s) tentative resistance breakpoints were determined. Fluconazole resistance-associated mutations were detected by PCR-sequencing of ERG11. All isolates identified as C. auris belonged to South Asian clade I and contained the ERG11 Y132F or K143R mutation. The Etest–MCN-AM EA was poor (33%) for fluconazole and moderate (76%) for AMB. The CA for fluconazole was higher (94.2%, 7 discrepancies) than for AMB (91.7%, 10 discrepancies). Discrepancies were reduced when an MCN-AM upper-limit value of 4 µg/mL for fluconazole-susceptible C. auris and an Etest upper-limit value of 8 µg/mL for the wild type for AMB were used. Our data show that resistance to fluconazole was underestimated by MCN-AM, while resistance to AMB was overestimated by Etest when using the CDC’s tentative resistance breakpoints of ≥32 µg/mL for fluconazole and ≥2 µg/mL for AMB. Method-specific resistance breakpoints should be devised for accurate AST of clinical C. auris isolates for proper patient management.
耐多药念珠菌最近在医疗机构中引起了大规模爆发。对念珠菌进行快速、准确的抗真菌药敏试验(AST)对于正确处理侵袭性感染至关重要。商用 Sensititre Yeast One 和 Vitek 2 方法会低估或高估真菌对氟康唑和两性霉素 B (AMB) 的耐药性。本研究通过梯度-MIC-条带(Etest)和基于肉汤微量稀释的 MICRONAUT-AM-EUCAST (MCN-AM)检测法,评估了球孢子菌对氟康唑和两性霉素 B(AMB)的 AST 检测结果。对通过表型和分子方法鉴定的临床阴道杆菌分离株(n = 121)进行了检测。确定了两种方法之间的基本一致(EA,±1 倍稀释)和基于美国疾病控制和预防中心(CDC)暂定耐药性断点的分类一致(CA)。通过对 ERG11 进行 PCR 测序,检测出与氟康唑耐药性相关的突变。所有被鉴定为阿氏杆菌的分离物都属于南亚支系 I,并含有 ERG11 Y132F 或 K143R 突变。对于氟康唑,Etest-MCN-AM 的 EA 较差(33%),对于 AMB,EA 中等(76%)。氟康唑的 CA 值(94.2%,7 个差异)高于 AMB(91.7%,10 个差异)。当使用对氟康唑敏感的阿米巴痢疾杆菌的 MCN-AM 上限为 4 µg/mL 和对 AMB 的野生型的 Etest 上限为 8 µg/mL 时,差异有所减少。我们的数据显示,当使用疾控中心暂定的耐药性断点(氟康唑≥32 µg/mL,AMB≥2 µg/mL)时,MCN-AM 低估了对氟康唑的耐药性,而 Etest 则高估了对 AMB 的耐药性。应设计出针对特定方法的耐药性断点,以便对临床分离出的球孢子菌进行准确的 AST 检测,从而对患者进行适当的管理。
{"title":"Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing of Candida auris: Underestimation of Fluconazole Resistance by MICRONAUT-AM and Overestimation of Amphotericin B Resistance by Etest","authors":"Mohammad Asadzadeh, Suhail Ahmad, Wadha Alfouzan, Inaam Al-Obaid, Bram Spruijtenburg, Eelco F. J. Meijer, Jacques F. Meis, Eiman Mokaddas","doi":"10.3390/antibiotics13090840","DOIUrl":"https://doi.org/10.3390/antibiotics13090840","url":null,"abstract":"Multidrug-resistant Candida auris has recently caused major outbreaks in healthcare facilities. Rapid and accurate antifungal susceptibility testing (AST) of C. auris is crucial for proper management of invasive infections. The Commercial Sensititre Yeast One and Vitek 2 methods underestimate or overestimate the resistance of C. auris to fluconazole and amphotericin B (AMB). This study evaluated the AST results of C. auris against fluconazole and AMB by gradient-MIC-strip (Etest) and broth microdilution-based MICRONAUT-AM-EUCAST (MCN-AM) assays. Clinical C. auris isolates (n = 121) identified by phenotypic and molecular methods were tested. Essential agreement (EA, ±1 two-fold dilution) between the two methods and categorical agreement (CA) based on the Centers for Disease Control and Prevention’s (CDC’s) tentative resistance breakpoints were determined. Fluconazole resistance-associated mutations were detected by PCR-sequencing of ERG11. All isolates identified as C. auris belonged to South Asian clade I and contained the ERG11 Y132F or K143R mutation. The Etest–MCN-AM EA was poor (33%) for fluconazole and moderate (76%) for AMB. The CA for fluconazole was higher (94.2%, 7 discrepancies) than for AMB (91.7%, 10 discrepancies). Discrepancies were reduced when an MCN-AM upper-limit value of 4 µg/mL for fluconazole-susceptible C. auris and an Etest upper-limit value of 8 µg/mL for the wild type for AMB were used. Our data show that resistance to fluconazole was underestimated by MCN-AM, while resistance to AMB was overestimated by Etest when using the CDC’s tentative resistance breakpoints of ≥32 µg/mL for fluconazole and ≥2 µg/mL for AMB. Method-specific resistance breakpoints should be devised for accurate AST of clinical C. auris isolates for proper patient management.","PeriodicalId":8151,"journal":{"name":"Antibiotics","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic Profiling of Antimicrobial Resistance Genes in Clinical Salmonella Isolates from Cattle in the Texas Panhandle, USA 美国得克萨斯州潘汉德尔地区牛临床沙门氏菌分离物中抗菌药耐药性基因的基因组分析
Pub Date : 2024-09-04 DOI: 10.3390/antibiotics13090843
Max Chung, Ethan Dudley, Hatem Kittana, Alexis C. Thompson, Matthew Scott, Keri Norman, Robert Valeris-Chacin
Rising antimicrobial resistance (AMR) in Salmonella serotypes host-adapted to cattle is of increasing concern to the beef and dairy industry. The bulk of the existing literature focuses on AMR post-slaughter. In comparison, the understanding of AMR in Salmonella among pre-harvest cattle is still limited, particularly in Texas, which ranks top five in beef and dairy exports in the United States; inherently, the health of Texas cattle has nationwide implications for the health of the United States beef and dairy industry. In this study, long-read whole genome sequencing and bioinformatic methods were utilized to analyze antimicrobial resistance genes (ARGs) in 98 isolates from beef and dairy cattle in the Texas Panhandle. Fisher exact tests and elastic net models accounting for population structure were used to infer associations between genomic ARG profiles and antimicrobial phenotypic profiles and metadata. Gene mapping was also performed to assess the role of mobile genetic elements in harboring ARGs. Antimicrobial resistance genes were found to be statistically different between the type of cattle operation and Salmonella serotypes. Beef operations were statistically significantly associated with more ARGs compared to dairy operations. Salmonella Heidelberg, followed by Salmonella Dublin isolates, were associated with the most ARGs. Additionally, specific classes of ARGs were only present within mobile genetic elements.
与牛宿主相适应的沙门氏菌血清型中抗菌药耐药性(AMR)的上升日益引起牛肉和乳制品行业的关注。现有文献主要关注屠宰后的 AMR。相比之下,人们对收获前牛体内沙门氏菌 AMR 的了解还很有限,尤其是在美国牛肉和乳制品出口量排名前五的得克萨斯州;得克萨斯州牛的健康状况对美国牛肉和乳制品行业的健康状况有着全国性的影响。本研究利用长线程全基因组测序和生物信息学方法分析了得克萨斯州潘汉德尔地区 98 个肉牛和奶牛分离物中的抗菌药耐药性基因 (ARGs)。利用费雪精确检验和考虑种群结构的弹性网模型来推断基因组 ARG 图谱与抗菌药表型图谱和元数据之间的关联。还进行了基因图谱绘制,以评估移动遗传因子在携带 ARGs 方面的作用。研究发现,不同养牛场类型和沙门氏菌血清型之间的抗菌药耐药性基因存在统计学差异。与奶牛饲养相比,牛肉饲养在统计学上与更多的 ARGs 相关。海德堡沙门氏菌与最多的 ARGs 相关,其次是都柏林沙门氏菌分离物。此外,特定类别的 ARGs 只存在于移动遗传因子中。
{"title":"Genomic Profiling of Antimicrobial Resistance Genes in Clinical Salmonella Isolates from Cattle in the Texas Panhandle, USA","authors":"Max Chung, Ethan Dudley, Hatem Kittana, Alexis C. Thompson, Matthew Scott, Keri Norman, Robert Valeris-Chacin","doi":"10.3390/antibiotics13090843","DOIUrl":"https://doi.org/10.3390/antibiotics13090843","url":null,"abstract":"Rising antimicrobial resistance (AMR) in Salmonella serotypes host-adapted to cattle is of increasing concern to the beef and dairy industry. The bulk of the existing literature focuses on AMR post-slaughter. In comparison, the understanding of AMR in Salmonella among pre-harvest cattle is still limited, particularly in Texas, which ranks top five in beef and dairy exports in the United States; inherently, the health of Texas cattle has nationwide implications for the health of the United States beef and dairy industry. In this study, long-read whole genome sequencing and bioinformatic methods were utilized to analyze antimicrobial resistance genes (ARGs) in 98 isolates from beef and dairy cattle in the Texas Panhandle. Fisher exact tests and elastic net models accounting for population structure were used to infer associations between genomic ARG profiles and antimicrobial phenotypic profiles and metadata. Gene mapping was also performed to assess the role of mobile genetic elements in harboring ARGs. Antimicrobial resistance genes were found to be statistically different between the type of cattle operation and Salmonella serotypes. Beef operations were statistically significantly associated with more ARGs compared to dairy operations. Salmonella Heidelberg, followed by Salmonella Dublin isolates, were associated with the most ARGs. Additionally, specific classes of ARGs were only present within mobile genetic elements.","PeriodicalId":8151,"journal":{"name":"Antibiotics","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of the COVID-19 Pandemic on Inpatient Antibiotic and Antifungal Drug Prescribing Volumes in Germany COVID-19 大流行对德国住院病人抗生素和抗真菌药物处方量的影响
Pub Date : 2024-09-03 DOI: 10.3390/antibiotics13090837
Winfried V. Kern, Michaela Steib-Bauert, Jürgen Baumann, Evelyn Kramme, Gesche Först, Katja de With
Background: Previous studies found that the coronavirus disease 2019 (COVID-19) pandemic had a variable impact on the consumption of antimicrobial drugs in human medicine, with trends in several European countries differing between community and inpatient prescribing. Aim: This study analysed changes in the volumes and use density of antibacterial and antifungal drugs dispensed in acute care hospitals in Germany between 2019 and 2022. Methods: Surveillance data for the four years available from 279 hospitals were expressed as the total volumes of daily doses or as use density (daily doses per 100 patient/occupied bed days) per year and analysed descriptively, using recommended hospital-adapted daily dose definitions (RDDs) and (as sensitivity analysis) WHO/ATC-defined daily dose definitions (DDD). Hospitals were stratified according to size (number of beds), university affiliation, and location (East, West, South). Results: There were significant decreases in both the total number of patient days and antibacterial drug volumes in 2020 through 2022 compared with 2019. The relative changes between 2019 and 2020, 2021, and 2022 were −12.8%, −13.5%, and −13.3% for patient days, and −9.7%, −11.0%, and −10.1% for antibacterial RDDs, respectively. Broad-spectrum betalactams, notably piperacillin–tazobactam and carbapenems, increased in volume, unlike most other drug classes. The resulting antibacterial drug use density was slightly but significantly increased, with pooled means (and medians) of 43.3 (40.0) RDD/100 in 2019 compared to 44.8 (41.7), 44.5 (40.80), and 44.9 (41.7) RDD/100 in the years 2020 through 2022, respectively. Antifungal drug volumes and use density increased after 2019 and peaked in 2021 (the difference between 2019 and 2021 for total volumes was +6.4%, and that for pooled mean use density values was +22.9%, respectively). These trends were similar in the different hospital strata and comparable when DDDs instead of RDDs were used. Conclusions: Similar to what has been observed in a majority of European countries, the total volume of antibacterial drug use in German acute care hospitals decreased with the pandemic, without a rebound phenomenon in 2022. In association with restricted hospital capacities and presumably more immunocompromised general medicine patients, however, inpatient prescribing of (primarily broad-spectrum) antibacterials and of antifungal drugs increased.
背景:以前的研究发现,2019 年冠状病毒病(COVID-19)大流行对人类医学中抗菌药物的消耗量产生了不同程度的影响,在几个欧洲国家,社区处方和住院处方的趋势各不相同。目的:本研究分析了 2019 年至 2022 年期间德国急诊医院抗菌药和抗真菌药配药量和使用密度的变化。研究方法使用推荐的医院适应性日剂量定义(RDDs)和(作为敏感性分析)WHO/ATC定义的日剂量定义(DDD),以每年日剂量总量或使用密度(每100名患者/占用床日的日剂量)表示279家医院四年来的监测数据,并进行描述性分析。根据医院规模(床位数)、所属大学和地理位置(东部、西部、南部)对医院进行了分层。结果与 2019 年相比,2020 年至 2022 年的患者总天数和抗菌药物用量均有明显下降。2019 年与 2020 年、2021 年和 2022 年之间的相对变化分别为:患者天数-12.8%、-13.5% 和-13.3%,抗菌药物 RDD-9.7%、-11.0% 和-10.1%。广谱β内酰胺类药物,特别是哌拉西林-他唑巴坦和碳青霉烯类药物的用量有所增加,这与其他大多数药物类别不同。由此产生的抗菌药物使用密度略有增加,但幅度较大,2019 年的合计平均值(和中位数)为 43.3 (40.0) RDD/100,而 2020 年至 2022 年的合计平均值(和中位数)分别为 44.8 (41.7)、44.5 (40.80) 和 44.9 (41.7) RDD/100。抗真菌药物的用量和使用密度在 2019 年后有所增加,并在 2021 年达到峰值(2019 年和 2021 年的总用量差值分别为 +6.4%,总平均使用密度差值为 +22.9%)。这些趋势在不同医院分层中相似,在使用 DDD 而不是 RDD 时也具有可比性。结论:与在大多数欧洲国家观察到的情况类似,德国急症医院的抗菌药物使用总量随着大流行而减少,但在 2022 年没有出现反弹现象。不过,由于医院能力有限,而且可能有更多免疫力低下的普通内科病人,住院病人开具的(主要是广谱)抗菌药和抗真菌药处方有所增加。
{"title":"Impact of the COVID-19 Pandemic on Inpatient Antibiotic and Antifungal Drug Prescribing Volumes in Germany","authors":"Winfried V. Kern, Michaela Steib-Bauert, Jürgen Baumann, Evelyn Kramme, Gesche Först, Katja de With","doi":"10.3390/antibiotics13090837","DOIUrl":"https://doi.org/10.3390/antibiotics13090837","url":null,"abstract":"Background: Previous studies found that the coronavirus disease 2019 (COVID-19) pandemic had a variable impact on the consumption of antimicrobial drugs in human medicine, with trends in several European countries differing between community and inpatient prescribing. Aim: This study analysed changes in the volumes and use density of antibacterial and antifungal drugs dispensed in acute care hospitals in Germany between 2019 and 2022. Methods: Surveillance data for the four years available from 279 hospitals were expressed as the total volumes of daily doses or as use density (daily doses per 100 patient/occupied bed days) per year and analysed descriptively, using recommended hospital-adapted daily dose definitions (RDDs) and (as sensitivity analysis) WHO/ATC-defined daily dose definitions (DDD). Hospitals were stratified according to size (number of beds), university affiliation, and location (East, West, South). Results: There were significant decreases in both the total number of patient days and antibacterial drug volumes in 2020 through 2022 compared with 2019. The relative changes between 2019 and 2020, 2021, and 2022 were −12.8%, −13.5%, and −13.3% for patient days, and −9.7%, −11.0%, and −10.1% for antibacterial RDDs, respectively. Broad-spectrum betalactams, notably piperacillin–tazobactam and carbapenems, increased in volume, unlike most other drug classes. The resulting antibacterial drug use density was slightly but significantly increased, with pooled means (and medians) of 43.3 (40.0) RDD/100 in 2019 compared to 44.8 (41.7), 44.5 (40.80), and 44.9 (41.7) RDD/100 in the years 2020 through 2022, respectively. Antifungal drug volumes and use density increased after 2019 and peaked in 2021 (the difference between 2019 and 2021 for total volumes was +6.4%, and that for pooled mean use density values was +22.9%, respectively). These trends were similar in the different hospital strata and comparable when DDDs instead of RDDs were used. Conclusions: Similar to what has been observed in a majority of European countries, the total volume of antibacterial drug use in German acute care hospitals decreased with the pandemic, without a rebound phenomenon in 2022. In association with restricted hospital capacities and presumably more immunocompromised general medicine patients, however, inpatient prescribing of (primarily broad-spectrum) antibacterials and of antifungal drugs increased.","PeriodicalId":8151,"journal":{"name":"Antibiotics","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detection of Antimicrobial Proteins/Peptides and Bacterial Proteins Involved in Antimicrobial Resistance in Raw Cow’s Milk from Different Breeds 检测不同品种生牛乳中的抗菌蛋白/肽和涉及抗菌素耐药性的细菌蛋白
Pub Date : 2024-09-03 DOI: 10.3390/antibiotics13090838
Cristian Piras, Rosario De Fazio, Antonella Di Francesco, Francesca Oppedisano, Anna Antonella Spina, Vincenzo Cunsolo, Paola Roncada, Rainer Cramer, Domenico Britti
Proteins involved in antibiotic resistance (resistome) and with antimicrobial activity are present in biological specimens. This study aims to explore the presence and abundance of antimicrobial peptides (AMPs) and resistome proteins in bovine milk from diverse breeds and from intensive (Pezzata rossa, Bruna alpina, and Frisona) and non-intensive farming (Podolica breeds). Liquid atmospheric pressure matrix-assisted laser desorption/ionization (LAP-MALDI) mass spectrometry (MS) profiling, bottom-up proteomics, and metaproteomics were used to comprehensively analyze milk samples from various bovine breeds in order to identify and characterize AMPs and to investigate resistome proteins. LAP-MALDI MS coupled with linear discriminant analysis (LDA) machine learning was employed as a rapid classification method for Podolica milk recognition against the milk of other bovine species. The results of the LAP-MALDI MS analysis of milk coupled with the linear discriminant analysis (LDA) demonstrate the potential of distinguishing between Podolica and control milk samples based on MS profiles. The classification accuracy achieved in the training set is 86% while it reaches 98.4% in the test set. Bottom-up proteomics revealed approximately 220 quantified bovine proteins (identified using the Bos taurus database), with cathelicidins and annexins exhibiting higher abundance levels in control cows (intensive farming breeds). On the other hand, the metaproteomics analysis highlighted the diversity within the milk’s microbial ecosystem with interesting results that may reflect the diverse environmental variables. The bottom-up proteomics data analysis using the Comprehensive Antibiotic Resistance Database (CARD) revealed beta-lactamases and tetracycline resistance proteins in both control and Podolica milk samples, with no relevant breed-specific differences observed.
生物样本中存在涉及抗生素耐药性(耐药性组)和具有抗菌活性的蛋白质。本研究旨在探讨不同品种、集约化养殖(Pezzata rossa、Bruna alpina 和 Frisona)和非集约化养殖(Podolica 品种)的牛乳中抗菌肽(AMPs)和抗生素组蛋白质的存在和丰度。研究人员利用液体常压基质辅助激光解吸/电离(LAP-MALDI)质谱(MS)分析、自下而上的蛋白质组学和元蛋白质组学对来自不同牛种的牛奶样本进行了全面分析,以确定AMPs的特征并研究抗性组蛋白质。将 LAP-MALDI MS 与线性判别分析 (LDA) 机器学习相结合,作为一种快速分类方法,用于识别 Podolica 牛奶与其他牛种牛奶的区别。对牛奶进行 LAP-MALDI MS 分析和线性判别分析(LDA)的结果表明,根据 MS 图谱区分 Podolica 牛奶样本和对照牛奶样本的潜力巨大。训练集的分类准确率为 86%,而测试集的准确率则达到 98.4%。自下而上的蛋白质组学发现了约 220 种量化的牛蛋白质(使用金牛数据库进行鉴定),对照组奶牛(集约化养殖品种)中的柔毛素和附件素含量较高。另一方面,元蛋白质组学分析强调了牛奶微生物生态系统的多样性,其有趣的结果可能反映了环境变量的多样性。使用抗生素耐药性综合数据库(CARD)进行的自下而上的蛋白质组学数据分析显示,对照组和 Podolica 牛奶样本中都有β-内酰胺酶和四环素耐药性蛋白质,没有观察到相关的品种特异性差异。
{"title":"Detection of Antimicrobial Proteins/Peptides and Bacterial Proteins Involved in Antimicrobial Resistance in Raw Cow’s Milk from Different Breeds","authors":"Cristian Piras, Rosario De Fazio, Antonella Di Francesco, Francesca Oppedisano, Anna Antonella Spina, Vincenzo Cunsolo, Paola Roncada, Rainer Cramer, Domenico Britti","doi":"10.3390/antibiotics13090838","DOIUrl":"https://doi.org/10.3390/antibiotics13090838","url":null,"abstract":"Proteins involved in antibiotic resistance (resistome) and with antimicrobial activity are present in biological specimens. This study aims to explore the presence and abundance of antimicrobial peptides (AMPs) and resistome proteins in bovine milk from diverse breeds and from intensive (Pezzata rossa, Bruna alpina, and Frisona) and non-intensive farming (Podolica breeds). Liquid atmospheric pressure matrix-assisted laser desorption/ionization (LAP-MALDI) mass spectrometry (MS) profiling, bottom-up proteomics, and metaproteomics were used to comprehensively analyze milk samples from various bovine breeds in order to identify and characterize AMPs and to investigate resistome proteins. LAP-MALDI MS coupled with linear discriminant analysis (LDA) machine learning was employed as a rapid classification method for Podolica milk recognition against the milk of other bovine species. The results of the LAP-MALDI MS analysis of milk coupled with the linear discriminant analysis (LDA) demonstrate the potential of distinguishing between Podolica and control milk samples based on MS profiles. The classification accuracy achieved in the training set is 86% while it reaches 98.4% in the test set. Bottom-up proteomics revealed approximately 220 quantified bovine proteins (identified using the Bos taurus database), with cathelicidins and annexins exhibiting higher abundance levels in control cows (intensive farming breeds). On the other hand, the metaproteomics analysis highlighted the diversity within the milk’s microbial ecosystem with interesting results that may reflect the diverse environmental variables. The bottom-up proteomics data analysis using the Comprehensive Antibiotic Resistance Database (CARD) revealed beta-lactamases and tetracycline resistance proteins in both control and Podolica milk samples, with no relevant breed-specific differences observed.","PeriodicalId":8151,"journal":{"name":"Antibiotics","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Clinical Characteristics and Outcomes with Daptomycin Use in Pediatric Patients: A Retrospective Case Series 在儿科患者中使用达托霉素的真实世界临床特征和结果:回顾性病例系列
Pub Date : 2024-09-02 DOI: 10.3390/antibiotics13090833
Hanna Persha, Stephen A. Thacker, Krutika Mediwala Hornback, Gustavo R. Alvira-Arill, Richard Lueking, Taylor Morrisette
Introduction: Daptomycin (DAP) is a cyclic lipopeptide that exhibits potent in vitro activity against many drug-resistant gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Despite substantial reports evaluating the clinical outcomes of DAP within the adult population, real-world data are lacking in children. The primary goal of this evaluation was to describe the clinical characteristics and outcomes of DAP use in pediatric patients across a wide range of infections. Methods: This retrospective evaluation included patients < 18 years of age who were treated with DAP from January 2014 to May 2023. The primary objective was to evaluate the composite clinical success, which was defined as a 30-day survival, the lack of a 30-day microbiological recurrence, and the resolution of signs and symptoms of an acute infection without therapy modifications based on clinical failures. Secondary objectives included adverse effects potentially attributable to DAP and reasons for DAP utilization. Results: Forty patients were included, which were predominately male (62.5%) and white (52.5%), with a median age of 8.7 [IQR, 4.4–16.0] years. DAP was used for a wide range of infections, including central line-associated bloodstream infections (CLABSIs; 32.5%), infective endocarditis (15.0%), surgical-site infections (12.5%), and osteomyelitis (12.5%). The most common pathogen isolated was MRSA (37.5%), and most patients were bacteremic (60.0%). The median DAP dose was 8 [IQR, 6–10] mg/kg, and the median duration of the DAP therapy was 11.5 [IQR, 4.8–18.8] days. Most patients achieved composite clinical success (75.0%). An adverse effect occurred in 5.0% of the patients. DAP was prescribed the most for its ease of use/ability to facilitate discharge (40.0%) and/or for issues with alternative therapies (37.5%). Conclusion: Most pediatric patients that received DAP demonstrated clinical success with a low incidence of adverse effects. Larger, real-world studies of DAP use are necessary to further assess clinical outcomes.
简介达托霉素(DAP)是一种环状脂肽,对许多耐药革兰氏阳性菌(包括耐甲氧西林金黄色葡萄球菌(MRSA)和耐万古霉素肠球菌(VRE))具有很强的体外活性。尽管有大量报告评估了 DAP 在成人人群中的临床效果,但缺乏儿童的实际数据。本次评估的主要目的是描述儿科患者在各种感染中使用 DAP 的临床特征和疗效。方法:这项回顾性评估纳入了 2014 年 1 月至 2023 年 5 月期间接受 DAP 治疗的年龄小于 18 岁的患者。首要目标是评估综合临床成功率,其定义为 30 天存活率、30 天内无微生物复发、急性感染症状和体征消失且未根据临床失败情况调整治疗方案。次要目标包括可能由 DAP 引起的不良反应以及使用 DAP 的原因。结果:共纳入 40 名患者,其中男性(62.5%)和白人(52.5%)占多数,中位年龄为 8.7 [IQR,4.4-16.0]岁。DAP 用于多种感染,包括中心静脉相关血流感染(CLABSIs;32.5%)、感染性心内膜炎(15.0%)、手术部位感染(12.5%)和骨髓炎(12.5%)。分离出的最常见病原体是 MRSA(37.5%),大多数患者为菌血症(60.0%)。DAP的中位剂量为8 [IQR,6-10] mg/kg,DAP治疗的中位持续时间为11.5 [IQR,4.8-18.8] 天。大多数患者取得了综合临床成功(75.0%)。5.0%的患者出现了不良反应。处方 DAP 最多的原因是其易于使用/便于出院(40.0%)和/或替代疗法存在问题(37.5%)。结论:大多数接受 DAP 治疗的儿科患者都取得了临床成功,不良反应发生率较低。有必要对 DAP 的使用情况进行更大规模的实际研究,以进一步评估临床效果。
{"title":"Real-World Clinical Characteristics and Outcomes with Daptomycin Use in Pediatric Patients: A Retrospective Case Series","authors":"Hanna Persha, Stephen A. Thacker, Krutika Mediwala Hornback, Gustavo R. Alvira-Arill, Richard Lueking, Taylor Morrisette","doi":"10.3390/antibiotics13090833","DOIUrl":"https://doi.org/10.3390/antibiotics13090833","url":null,"abstract":"Introduction: Daptomycin (DAP) is a cyclic lipopeptide that exhibits potent in vitro activity against many drug-resistant gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Despite substantial reports evaluating the clinical outcomes of DAP within the adult population, real-world data are lacking in children. The primary goal of this evaluation was to describe the clinical characteristics and outcomes of DAP use in pediatric patients across a wide range of infections. Methods: This retrospective evaluation included patients < 18 years of age who were treated with DAP from January 2014 to May 2023. The primary objective was to evaluate the composite clinical success, which was defined as a 30-day survival, the lack of a 30-day microbiological recurrence, and the resolution of signs and symptoms of an acute infection without therapy modifications based on clinical failures. Secondary objectives included adverse effects potentially attributable to DAP and reasons for DAP utilization. Results: Forty patients were included, which were predominately male (62.5%) and white (52.5%), with a median age of 8.7 [IQR, 4.4–16.0] years. DAP was used for a wide range of infections, including central line-associated bloodstream infections (CLABSIs; 32.5%), infective endocarditis (15.0%), surgical-site infections (12.5%), and osteomyelitis (12.5%). The most common pathogen isolated was MRSA (37.5%), and most patients were bacteremic (60.0%). The median DAP dose was 8 [IQR, 6–10] mg/kg, and the median duration of the DAP therapy was 11.5 [IQR, 4.8–18.8] days. Most patients achieved composite clinical success (75.0%). An adverse effect occurred in 5.0% of the patients. DAP was prescribed the most for its ease of use/ability to facilitate discharge (40.0%) and/or for issues with alternative therapies (37.5%). Conclusion: Most pediatric patients that received DAP demonstrated clinical success with a low incidence of adverse effects. Larger, real-world studies of DAP use are necessary to further assess clinical outcomes.","PeriodicalId":8151,"journal":{"name":"Antibiotics","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142196207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Antibiotics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1